Schering Intron A hepatitis B pediatric supplement filed Sept. 2.
SCHERING INTRON A PEDIATRIC SUPPLEMENT submitted Sept. 2 seeks an indication for the recombinant interferon alfa-2b product for the treatment of hepatitis B in patients one to 17 years of age. The supplemental BLA is based on Phase IV study data, Schering-Plough says. Intron A is currently marketed for adults as a treatment for hepatitis B, chronic hepatitis C, malignant melanoma and hairy cell leukemia.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth